PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma.
about
MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein functionMechanisms of impaired differentiation in rhabdomyosarcomaInducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expressionmiR-206 and -486 induce myoblast differentiation by downregulating Pax7Genetic and molecular abnormalities in tumors of the bone and soft tissues.Pax7 activates myogenic genes by recruitment of a histone methyltransferase complex.Genome-wide discovery of Pax7 target genes during development.The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo.Thrombin regulates the metastatic potential of human rhabdomyosarcoma cells: distinct role of PAR1 and PAR3 signaling.An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogeneOverlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomasGenome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas.Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblastsDiscovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis.PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcomaGene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors.Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group.Chromosomal translocations highlighted in Primitive Neuroectodermal Tumors (PNET) and Ewing sarcoma.PAX Genes in Cancer; Friends or Foes?Oncorhynchus mykiss pax7 sequence variations with comparative analyses against other teleost speciesReciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination.Persistent expression of Pax3 in the neural crest causes cleft palate and defective osteogenesis in miceMarking the tempo for myogenesis: Pax7 and the regulation of muscle stem cell fate decisionsCaveolins in rhabdomyosarcomaA call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications.Cloning and characterization of the human PAX7 promoter.Pax7-FKHR transcriptional activity is enhanced by transcriptionally repressed MyoD.Pioneer transcription factors shape the epigenetic landscape.Quantitative DNA methylation analysis of paired box gene 1 and LIM homeobox transcription factor 1 α genes in cervical cancer.
P2860
Q24540167-C0D12BEB-B4F6-4BA3-B9A7-67A68A7B989CQ26852728-2843CDFC-BAF1-445A-872B-19FDD4B82EA2Q28265800-863785AC-62F9-4018-880C-D41CB25C4C54Q30431651-979B3E8F-3A4F-4FE2-B715-E26D370A3B30Q30990686-66315E4C-F52F-489F-97CC-092C0014B237Q33309162-61013F76-91DC-4B3A-9062-1C9AB42A51DDQ33315000-AB59709D-F301-48AA-9036-F9F98B995D31Q33938529-48F15625-5A18-4B61-B9E3-70D5C02587F2Q33959220-B786572F-5FBE-4095-9390-BFC6F9CEF04EQ33964561-17EDE0FD-DC57-4B5B-932F-BCEEB2AFEBAFQ34009162-5B136B58-884A-42C4-9686-933E022B7226Q34069048-424111DB-4A1D-461C-82F1-B59D037A61B9Q34146951-5A4C0E5E-4001-418D-9357-EE7E68402983Q34280104-1379855B-4645-43BF-B2EE-E6D626F79AC1Q34359802-5A644CD9-CDB2-49AA-9FED-D8A03819A4B7Q34363846-41651B12-86BE-4A1F-A7B8-FF40419BC30EQ34405491-BEC56F19-2509-4097-935C-F34578B1D5BFQ34441929-6BC54946-E686-49DA-A34A-D75A61D0E2AEQ34578460-4A9BECEB-515E-438B-AF98-6C86FE180302Q35340365-7C89358B-1DB9-4291-8ABD-CB104024740BQ35714437-3568D2AA-82CF-4A43-94C7-75FD1C1D75AEQ35749041-E0CF1DC5-558D-49C7-B715-CB9C8B5078A5Q36118440-AF64DEA5-FC83-4811-9FAC-77BE54846C20Q36655020-A6EC2E2E-46B8-4F21-B53C-34839957A578Q37880238-6FB278E9-D028-4C78-8806-E1AA4F93DF0FQ37894860-D95F11D4-22EF-498F-A0AA-B5C9847344E4Q38083828-2769FE2B-DECE-4361-B838-D45E6F354A63Q39636176-24DE20C9-C8C3-4974-A1BD-187C6E38B985Q42488803-0DB97DC1-8DBA-4E0A-A04D-F1044D8BA68CQ42711044-40229154-CA08-489D-A885-47FE53F37762Q50532548-7642D0B0-D8D6-4AF6-AD24-4A93F3A114ACQ52726492-0F4E775B-3F70-4EB5-97DF-58F8FE2979EE
P2860
PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
PAX3 and PAX7 exhibit conserve ...... in alveolar rhabdomyosarcoma.
@en
PAX3 and PAX7 exhibit conserve ...... in alveolar rhabdomyosarcoma.
@nl
type
label
PAX3 and PAX7 exhibit conserve ...... in alveolar rhabdomyosarcoma.
@en
PAX3 and PAX7 exhibit conserve ...... in alveolar rhabdomyosarcoma.
@nl
prefLabel
PAX3 and PAX7 exhibit conserve ...... in alveolar rhabdomyosarcoma.
@en
PAX3 and PAX7 exhibit conserve ...... in alveolar rhabdomyosarcoma.
@nl
P2093
P2860
P356
P1433
P1476
PAX3 and PAX7 exhibit conserve ...... in alveolar rhabdomyosarcoma.
@en
P2093
B W Schäfer
J L Bennicelli
P2860
P2888
P304
P356
10.1038/SJ.ONC.1202812
P407
P577
1999-07-01T00:00:00Z
P5875
P6179
1034932752